Yoojoo T. Lim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.

Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.

Journal: JCO global oncology

Published: April 10, 2026

CEBPB Expression in Tumor Cells Drives Immune Evasion in Colorectal Cancer via CTLA4 Up-regulation in T Cells.

CEBPB Expression in Tumor Cells Drives Immune Evasion in Colorectal Cancer via CTLA4 Up-regulation in T Cells.

Journal: Cancer communications (London, England)

Published: December 30, 2025

Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer.

Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer.

Journal: JAMA surgery

Published: June 25, 2025

PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Journal: Oral surgery, oral medicine, oral pathology and oral radiology

Published: June 12, 2025

Differential implications of tumor endothelial cell and lymphocyte densities in advanced hepatocellular carcinoma patients treated with immunotherapy.

Differential implications of tumor endothelial cell and lymphocyte densities in advanced hepatocellular carcinoma patients treated with immunotherapy.

Journal: NPJ precision oncology

Published: June 04, 2025

Predictive role of tumor-infiltrating lymphocytes and immune phenotype for pembrolizumab in relapsed or refractory thymic carcinoma.

Predictive role of tumor-infiltrating lymphocytes and immune phenotype for pembrolizumab in relapsed or refractory thymic carcinoma.

Journal: Journal of thoracic disease

Published: March 12, 2025

Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer.

Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer.

Journal: Anticancer research

Published: February 12, 2025

Comparison of Tumor Microenvironments between Primary Tumors and Lymph Node Metastases in Head and Neck Squamous Cell Carcinoma and Their Predictive Role in Immune Checkpoint Inhibitor Treatment.

Comparison of Tumor Microenvironments between Primary Tumors and Lymph Node Metastases in Head and Neck Squamous Cell Carcinoma and Their Predictive Role in Immune Checkpoint Inhibitor Treatment.

Journal: Cells

Published: August 20, 2024

Neoadjuvant Chemotherapy Response in Triple-Negative Apocrine Carcinoma: Comparing Apocrine Morphology, Androgen Receptor, and Immune Phenotypes.

Neoadjuvant Chemotherapy Response in Triple-Negative Apocrine Carcinoma: Comparing Apocrine Morphology, Androgen Receptor, and Immune Phenotypes.

Journal: Archives of pathology & laboratory medicine

Published: May 24, 2024

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer.

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 26, 2024

Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors.

Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors.

Journal: Discover oncology

Published: March 15, 2024

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.

Journal: Journal for immunotherapy of cancer

Published: January 27, 2024

Showing 1-12 of 43

Last Updated: 09/26/2026